The European Medicines Agency (EMA) recently adopted a positive opinion extending the use of Stelara (ustekinumab) for children with Crohn’s disease who weigh at least 40kg.

As we embark on a new year, our communication team has been working behind the scenes to bring you closer to the EFCCA community.

EFCCA is proud to partner in the innovative INTERCEPT IHI project, which aims to revolutionise the approach to Crohn’s dvisease by focusing on prevention and early intervention.

EFCCA brought together top researchers, industry experts and patient advocates for a webinar on intestinal fibrosis in IBD

Following the success of our HTA conference at UEGW last October, EFCCA is pleased to share the final report from a two-round consultation with stakeholders and experts.

On 20 February 2025, at the 20th ECCO Congress in Berlin, we hosted our conference: "What do IBD patients find important in their treatment? Results from a global Patient Preference survey."

This non-invasive technique is emerging as a valuable tool for diagnosis, treatment, and disease monitoring in IBD patients.

Aiming to revolutionise personalised prevention and early treatment in chronic inflammatory diseases (CIDs), the PerPrev-CID project focuses on advancing risk prediction, early detection of disease progression, and innovative preventive approaches in rheumatoid arthritis (RA) and Inflammatory Bowel Disease (IBD).